Gina Kolata and Rebecca Robbins report on the significant breakthrough in pancreatic cancer treatment with daraxonrasib, a drug that has shown promise in prolonging the lives of patients by targeting the resilient KRAS protein, marking a potential landmark advancement in cancer therapy after decades of research impediments. #PancreaticCancer #CancerResearch #ExperimentalDrug #US
www.nytimes.com
El cáncer de páncreas tiene un gran avance
